130 Eileen Stubbs Avenue
Dartmouth, NS B3B 2C4
Full Time Employees: 97
|Mr. Andrew Hall M.Sc.||CEO & Director||273.71k||N/A||N/A|
|Ms. Brittany Davison C.A., CPA||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeremy R. Graff||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Joy Bessenger B.A.||Sr. VP of Investor Relations & Corp. Strategy||N/A||N/A||N/A|
|Ms. Annie Tanguay B.Sc.||Sr. VP of Quality & Compliance||N/A||N/A||N/A|
|Delphine Davan||Sr. Director of Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Linda Barabe M.B.A.||VP of HR||N/A||N/A||N/A|
|Dr. Marianne Stanford||VP of R&D||N/A||N/A||N/A|
|Mr. Stephan Fiset||VP of Clinical Research||N/A||N/A||N/A|
|Dr. Heather Hirsch||VP of Translational Research||N/A||N/A||N/A|
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IMV Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 7; Compensation: 3.